35.29
0.05 (0.14%)
| Previous Close | 35.24 |
| Open | 35.59 |
| Volume | 1,197,322 |
| Avg. Volume (3M) | 1,651,300 |
| Market Cap | 5,616,721,408 |
| Price / Earnings (Forward) | 90.91 |
| Price / Sales | 10.13 |
| Price / Book | 15.45 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
| Profit Margin | -63.86% |
| Operating Margin (TTM) | -111.59% |
| Diluted EPS (TTM) | -2.99 |
| Quarterly Revenue Growth (YOY) | 10.10% |
| Total Debt/Equity (MRQ) | 413.80% |
| Current Ratio (MRQ) | 9.66 |
| Operating Cash Flow (TTM) | -501.78 M |
| Levered Free Cash Flow (TTM) | -368.16 M |
| Return on Assets (TTM) | -10.59% |
| Return on Equity (TTM) | -118.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Ionis Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.63 |
|
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.83% |
| % Held by Institutions | 108.17% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tweedy, Browne Co Llc | 31 Dec 2024 | 3,248,863 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 96.00 (Jefferies, 172.03%) | Buy |
| Median | 70.00 (98.36%) | |
| Low | 45.00 (Goldman Sachs, 27.52%) | Sell |
| Average | 70.43 (99.58%) | |
| Total | 11 Buy, 2 Hold, 1 Sell | |
| Avg. Price @ Call | 52.03 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 04 Sep 2025 | 80.00 (126.69%) | Buy | 59.35 |
| BMO Capital | 03 Sep 2025 | 70.00 (98.36%) | Buy | 60.49 |
| Barclays | 03 Sep 2025 | 78.00 (121.03%) | Buy | 60.49 |
| 22 Aug 2025 | 58.00 (64.35%) | Buy | 42.69 | |
| Citigroup | 03 Sep 2025 | 84.00 (138.03%) | Buy | 60.49 |
| 22 Aug 2025 | 69.00 (95.52%) | Buy | 42.69 | |
| Goldman Sachs | 03 Sep 2025 | 45.00 (27.51%) | Sell | 60.49 |
| HC Wainwright & Co. | 02 Sep 2025 | 95.00 (169.20%) | Buy | 57.49 |
| 22 Aug 2025 | 70.00 (98.36%) | Buy | 42.69 | |
| Jefferies | 02 Sep 2025 | 96.00 (172.03%) | Buy | 57.49 |
| Needham | 02 Sep 2025 | 70.00 (98.36%) | Buy | 57.49 |
| 25 Aug 2025 | 55.00 (55.85%) | Buy | 41.82 | |
| JP Morgan | 25 Aug 2025 | 49.00 (38.85%) | Hold | 41.82 |
| 12 Jun 2025 | 48.00 (36.02%) | Hold | 35.62 | |
| Piper Sandler | 22 Aug 2025 | 65.00 (84.19%) | Buy | 42.69 |
| Wells Fargo | 22 Aug 2025 | 82.00 (132.36%) | Buy | 42.69 |
| UBS | 12 Aug 2025 | 46.00 (30.35%) | Hold | 41.41 |
| Morgan Stanley | 31 Jul 2025 | 62.00 (75.69%) | Buy | 42.98 |
| Raymond James | 31 Jul 2025 | 64.00 (81.35%) | Buy | 42.98 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |